Article thumbnail
Location of Repository

Current implications of cyclophilins in human cancers

By Jinhwa Lee and Sung Soo Kim
Topics: Review
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2912272
Provided by: PubMed Central

Suggested articles

Citations

  1. (2006). AJ: The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res
  2. (2006). Ali IU: Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells. Cancer Epidemiol Biomarkers Prev
  3. (2008). AT: Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncol Rep
  4. (2010). BC: Oxidative stress and vascular smooth muscle cell growth: a mechanistic linkage by cyclophilin a. Antioxid Redox Signal
  5. (2003). Bieniasz PD: Cyclophilin A modelates the sensitivity of HIV-1 to host restriction factors. Nat Med
  6. (2005). Biochemistry: A pore way to die. Nature
  7. (1998). Cattley RC: Cloning genes responsive to a hepatocarcinogenic peroxisome proliferator chemical reveals novel targets of regulation. Cancer Lett
  8. (2009). CV: Expression of cyclophilin B is associated progression and regulation with malignant of genes implicated in pathogenesis of breast cancer.
  9. (2008). CV: Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer. Cancer Res
  10. (2006). Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer
  11. (2007). Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal. Biochem Biophys Res Commun
  12. (2007). Del Sal G: The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol
  13. (2005). Effect of cyclophilin A on gene expression in human pancreatic cancer cells.
  14. (2009). Efferth T: Natural products as promising drug candidates for the treatment of hepatitis B and C. Acta Pharmacol Sin
  15. (1999). Expression of the estrogen receptor-associated immunophilins, cyclophilin 40 and FKBP52, in breast cancer. Breast Cancer Res Treat
  16. (2002). Fenselau C: Differential protein expression in the cytosol fraction of an MCF-7 breast cancer cell line selected for resistance toward melphalan.
  17. (2008). GB: Comparative proteomic analysis of matched primary and metastatic melanoma cell lines.
  18. (2001). Human cyclophilin 40 is a heat shock protein that exhibits altered intracellular localization following heat shock. Cell Stress Chaperones
  19. (1992). Immunophilin-sensitive protein phosphatase action in cell signaling pathways. Cell
  20. (1996). Involvement of cyclophilin D in the activation of a mitochondrial pore by Ca2+ and oxidant stress.
  21. (1999). Itoh K: A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumorspecific CTLs.
  22. (2008). JF: Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma.
  23. (2006). Knuckey NW: Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptormediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury. Neurobiol Dis
  24. (2002). Lechleiter JD: Mitochondrial targeted cyclophilin D protects cells from cell death by peptidyl prolyl isomerization.
  25. (1999). Marahiel MA: Peptidyl-prolyl cis-trans isomerase, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci
  26. (1995). Nabeshima K: The human tumor cell derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res
  27. (1993). Ortaldo JR: A cyclophilin-related protein involved in the function of natural killer cells.
  28. (2005). Patz EF Jr: Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res
  29. (2004). Patz EF Jr: Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer
  30. (2007). PC: Thrombin-cleaved COOH-terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Res
  31. (2003). Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity targets functions. Curr Top Med Chem
  32. (2003). PG: Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2'-deoxycytidine. Electrophoresis
  33. (1998). Prolyl isomerase and nuclear function. Cell
  34. (2004). Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by twodimensional gel electrophoresis and mass spectrometry. Cancer Res
  35. (2003). Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res
  36. (1995). Protein folding. Prolyl isomerase join the fold. Curr Biol
  37. (2002). Proteome analysis of hepatocellular carcinoma.
  38. (2004). Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumorigenesis. Proteomics
  39. (2005). Regulation of CD147 cell surface expression: involvement of the proline residue in the CD147 transmembrane domain.
  40. (2008). S: Monitoring mouse prostate development by profiling and imaging mass spectrometry. Molecular & Cellular Proteomics
  41. (2007). Sakaida I, Nakamura K: Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry.
  42. (1991). Schreiber SL: Calcineurin is a common target of cyclophilin-cyclosporine A and FKBP-FK506 complexes. Cell
  43. (1993). Sigal N: The mechanism of action of FK- 506 and cyclosporine A. Ann NY Acad Sci
  44. (2002). SS: Cyclosporine A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporine A-induced cytotoxicity.
  45. (2010). SS: Cyclosproin A and sanglifehrin A enhance chemotherapeutic effect of cisplatin in C6 glioma cells. Oncol Rep
  46. (2007). SS: Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res
  47. (2001). T: Allelic loss of cyclophilin 40, an estrogen receptor-associated immunophilin, in breast carcinomas.
  48. (2009). TE: Cyclophilin D interacts with Bcl2 and exerts an anti-apoptotic effect.
  49. (1998). The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2- related proteins.
  50. (1999). Transcription of actin, cyclophilin and glyceraldehyde phosphate dehydrogenase genes: Tissue- and treatment-specificity. Biochimica et Biophysica Acta - Gene Structure and Expression
  51. (2005). von Eggeling F: Identification of proteins from colorectal cancer tissue by twodimensional gel electrophoresis and SELDI mass spectrometry.
  52. (2004). X: Global investigation of p53-induced apoptosis through quantitative proteomic profiling using comparative amino acid-coded tagging. Mol Cell Proteomics
  53. (1998). Zarnt T: The mode of action of peptidyl prolyl cis/ trans isomerase in vivo: Binding vs catalysis. FEBS Lett
  54. (1994). Zuker CS: Protein folding and the regulation of signaling pathways. Cell

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.